Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice

Bipolar Disorders

Volumn 17, Issue 6, 2015, Pages 615-625

  Wlodarczyk, Bogdan J ^a   Ogle, Krystal ^a   Lin, Linda Ying ^a   Bialer, Meir ^b   Finnell, Richard H ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Comparative teratogenicity; Mice; Olanzapine; Risperidone; Valnoctamide

Indexed keywords

OLANZAPINE; RISPERIDONE; VALNOCTAMIDE; AMIDE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; BONE DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; FETAL WELL BEING; FETOTOXICITY; FETUS DEATH; LD50; MOUSE; NONHUMAN; PRENATAL DRUG EXPOSURE; PRENATAL PERIOD; PRIORITY JOURNAL; TERATOGENICITY; TREATMENT INDICATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; TERATOGENESIS;

AMIDES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; PREGNANCY; PREGNANCY COMPLICATIONS; RISPERIDONE; TERATOGENESIS;

EID: 84941022498     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12325     Document Type: Article

References (44)

1. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991; 20: 114-122.
2. Stepansky W. A clinical study on the use of valmethamide, an anxiety-reducing drug. Curr Ther Res Clin Exp 1960; 2: 144-147.
3. Bialer M, Yagen B. Valproic acid - second generation. Neurotherapeutics 2007; 4: 130-137.
4. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010; 9: 68-83.
5. Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 2013; 54 (Suppl. 6): 99-102.
6. Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980; 97: 332-333.
7. Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology 1987; 35: 465-473.
8. Nau H, Headrick X. Valproic acid teratogenesis. ISI Atlas Sci Pharmacol 1987; 1: 52-56.
9. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
10. Menegola E, Di Renzo F, Broccia ML et al. Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. Birth Defects Res B Dev Reprod Toxicol 2005; 74: 392-398.
11. Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998; 30: 41-48.
12. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013; 103: 2-30.
13. Shekh-Ahmad T, Hen N, Yagen B et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014; 55: 353-361.
14. Shaltiel G, Shamir A, Shapiro J et al. Valproate decreases inositol biosynthesis. Biol Psychiatry 2004; 56: 868-874.
15. Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myoinositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep 2007; 59: 402-407.
16. Modi HR, Basselin M, Rapoport SI. Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4. Bipolar Disord 2014; 16: 875-880.
17. Shimshoni JA, Basselin M, Li LO, Coleman RA, Rapoport SI, Modi HR. Valproate uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: relevance to valproate's efficacy against bipolar disorder. Biochim Biophys Acta 2011; 1811: 163-169.
18. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2009; 2: 207-214.
19. Bersudsky Y, Applebaum J, Gaiduk Y et al. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial. Bipolar Disord 2010; 12: 376-382.
20. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015; 111: 85-141.
21. Tomson T, Battino D, Bonizzoni E et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10: 609-617.
22. Meador KJ, Baker GA, Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360: 1597-1605.
23. European Medicines Agency (EMA) website: EMA/612389/2014. PRAC Recommends Strengthening the Restrictions on the Use of Valproate in Women and Girls. Available from: www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500175208.pdf [accessed January 2014].
24. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010; 36: 518-544.
25. Zyprexa. Prescribing Information. Available from: http://pi.lilly.com/us/zyprexa-pi.pdf [accessed January 2014].
26. Risperidone. Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056, 020588s044, 021346s033, 021444s03lbl.pdf [accessed January 2014].
27. Olanzapine. Prescribing Information. Available from: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con123101.pdf [accessed January 2014].
28. Isoherranen N, Yagen B, Spiegelstein O et al. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Br J Pharmacol 2003; 139: 755-764.
29. Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J Med Chem 2007; 50: 6419-6427.
30. Pessah N, Kaufmann D, Yagen B et al. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2, 2, 3, 3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. Epilepsia 2010; 51: 1944-1953.
31. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Pharmacology and Toxicology, 2005. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf [accessed January 2014].
32. Snell GD, Fekete E, Hummel KP, Law LW. The relation of mating, ovulation and the estrous smear in the house mouse to time of day. Anat Rec 1940; 76: 39-54.
33. Kimmel CA, Trammell C. A rapid procedure for routine double staining of cartilage and bone in fetal and adult animals. Stain Technol 1981; 56: 271-273.
34. Wilson JC. Methods for administering agents and detecting malformations in experimental animals. In: Wilson JG, Warkany J eds. Teratology: Principles and Techniques. Chicago, IL: Press Syndicate of the University of Chicago, 1965: 262-277.
35. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64: 887-895.
36. Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M. Amidic modification of valproic acid reduces skeletal teratogenicity in mice. Birth Defects Res B Dev Reprod Toxicol 2004; 71: 47-53.
37. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmacoepidemiological studies. Acta Psychiatr Scand 2010; 121: 4-10.
38. Toh S, Li Q, Cheetham TC et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585, 615 deliveries. Arch Womens Men Health 2013; 16: 149-157.
39. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry 2013; 202: 321-323.
40. Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol 2015; 116: 315-320.
41. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-198.
42. Harden CL, Meador KJ, Pennell PB et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50: 1237-1246.
43. Nguyen HT, Sharma V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009; 26: 281-294.
44. Fabro S, Shull G, Brown NA. The relative teratogenic index and teratogenic potency: proposed components of developmental toxicity risk assessment. Teratog Carcinog Mutagen 1982; 2: 61-76.